Bio-Rad Laboratories, Inc. (BIO.B)

Bio-Rad Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	521.4	488.1	403.8	434.22	470.78	662.21
Short-Term Investments	1,139	1,176	1,203	1,356	399.14	328.91
Cash & Short-Term Investments	1,660	1,665	1,607	1,791	869.92	991.12
Cash Growth	0.90%	3.57%	-10.25%	105.84%	-12.23%	-11.08%
Accounts Receivable	424.7	452.5	489	494.65	423.54	419.42
Other Receivables	13.7	13.1	11.9	11.6	2.2	1.4
Receivables	438.4	465.6	500.9	506.25	425.74	420.82
Inventory	790.1	760	780.5	719.32	572.24	622.25
Prepaid Expenses	125.4	122.6	140	124.18	109.14	90.62
Restricted Cash	1.3	1.4	0.2	0.01	0.01	3.99
Other Current Assets	21	16.2	19.6	17.55	13.44	11.03
Total Current Assets	3,037	3,030	3,048	3,158	1,990	2,140
Property, Plant & Equipment	681.7	688.6	723.7	679.56	716.44	693.51
Long-Term Investments	4,993	4,838	7,697	8,830	14,386	9,560
Goodwill	414.6	410.5	413.6	406.49	347.34	291.92
Other Intangible Assets	296.1	293.6	320.5	332.15	253.94	199.5
Other Long-Term Assets	105	103.5	96.4	95.8	105.49	87.82
Total Assets	9,527	9,364	12,299	13,502	17,799	12,973
Accounts Payable	137.9	122.3	144.6	135.04	141.94	139.45
Accrued Expenses	157.4	124.2	139.9	194.79	312.97	256.93
Current Portion of Long-Term Debt	0.7	0.8	-	-	-	1.3
Current Portion of Leases	41.8	42.1	40.9	36.8	36.92	37.01
Current Income Taxes Payable	37.1	31.2	35.8	32.43	10.32	23.28
Current Unearned Revenue	-	-	-	-	50.85	42.47
Other Current Liabilities	131.7	147.2	161.6	169.65	127.94	131.1
Total Current Liabilities	506.6	467.8	522.8	568.71	680.94	631.54
Long-Term Debt	1,192	1,191	1,190	1,188	0	1.26
Long-Term Leases	135.3	140.6	175.1	163.73	186.45	186.13
Long-Term Deferred Tax Liabilities	840.8	818	1,476	1,770	3,065	2,077
Other Long-Term Liabilities	173.1	120.3	135.5	150.61	108.39	102.17
Total Liabilities	2,848	2,795	3,558	3,886	4,114	3,093
Common Stock	-	-	-	0	0	0
Additional Paid-In Capital	475.7	463.2	449.1	447.45	441.73	429.38
Retained Earnings	7,480	7,416	9,261	9,898	13,525	9,268
Treasury Stock	-866.9	-772.1	-632.5	-263.59	-106.29	-99.91
Comprehensive Income & Other	-409.8	-538.2	-336	-466.82	-175.55	282.46
Shareholders' Equity	6,679	6,569	8,741	9,615	13,685	9,880
Total Liabilities & Equity	9,527	9,364	12,299	13,502	17,799	12,973
Total Debt	1,370	1,375	1,406	1,388	223.38	225.69
Net Cash (Debt)	290.9	289.8	201.6	402.56	646.54	765.43
Net Cash Growth	18.27%	43.75%	-49.92%	-37.74%	-15.53%	65.14%
Net Cash Per Share	10.36	10.27	6.90	13.52	21.40	25.38
Filing Date Shares Outstanding	27.21	28.01	28.52	29.6	29.93	29.84
Total Common Shares Outstanding	27.63	28.01	28.52	29.6	29.93	29.84
Working Capital	2,530	2,563	2,526	2,589	1,310	1,508
Book Value Per Share	241.72	234.52	306.51	324.89	457.20	331.05
Tangible Book Value	5,969	5,865	8,007	8,877	13,084	9,389
Tangible Book Value Per Share	216.00	209.39	280.77	299.93	437.12	314.59
Land	-	27.8	28.4	27.8	27.94	25.74
Buildings	-	426.3	419.8	393.6	385.8	363.05
Machinery	-	1,183	1,148	1,087	1,100	1,064

Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q